KalVista Reports Positive Phase II Data For Oral HAE Attack Therapy KVD900
Drug Appears Well Positioned Vs. Approved Therapies
Executive Summary
The company sees KVD900 as potentially “ideal” for patients using on-demand and prophylactic therapy, given the existing need to carry backup on-demand medications.